Abstract | OBJECTIVE: METHODS: From 1987 to 2006, 265 Hr-HM were selected in a retrospective analysis of a nonrandomized clinical trial of 1090 patients with gestational trophoblastic disease (GTD) followed up at a Trophoblastic Disease Center (TDC) in southern Brazil. From 1996 to 2006, 163 received a single bolus dose of Act- D at time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-Chem (Hr-HM-control group). Variables were: number of patients with postmolar GTN who required chemotherapy during follow-up, postmolar GTN morbidity, compliance and operational costs. RESULTS: Postmolar GTN was diagnosed in 18.4% of the Hr-HM-chem patients (95% CI: 12.7-24.7) and in 34.3% of the Hr-HM-control patients (95% CI: 25.1-43.5). Postmolar GTN was 46% lower in P-Chem (RR=0.54; 95% CI: 0.35-0.82; NNT=7). P-Chem adverse effects were occasional and minor. When disease progressed to postmolar GTN, severity was the same, but costs were lower for the Hr-HM-chem group. Compliance with follow-up was high and similar in both groups. CONCLUSIONS: Follow-up of patients with Hr-HM showed that a single bolus dose of prophylactic Act-D reduced the incidence of postmolar GTN. Compliance and postmolar GTN morbidity were not affected. Treatment costs and emotional complications were reduced. This prophylactic approach can be adopted before uterine evacuation in any TDC that treats Hr-HM patients that present with undelivered moles.
|
Authors | Elza Maria Hartmann Uberti, Maria do Carmo Fajardo, Adriana Gerhardt Vieira da Cunha, Marcos Wengrover Rosa, Antonio Celso Koehler Ayub, Márcia da Silveira Graudenz, Helena Schmid |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 114
Issue 2
Pg. 299-305
(Aug 2009)
ISSN: 1095-6859 [Electronic] United States |
PMID | 19427681
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Dactinomycin
|
Topics |
- Adult
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Dactinomycin
(adverse effects, therapeutic use)
- Female
- Gestational Trophoblastic Disease
(pathology, prevention & control)
- Humans
- Hydatidiform Mole
(drug therapy, pathology, surgery)
- Pregnancy
- Retrospective Studies
|